Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
Predictive imaging biomarkers on whole-body diffusion-weighted MRI (WB-DWMRI) and [68Ga]GaPSMA-PET/CT for [177Lu]LuPSMA therapy in metastatic prostate cancer (mCRPC).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Padden-Modi Minal, Taprogge Jan, Dutey-Magni Peter, Cauduro Carolina G S, Blackledge Matthew D, Abdel-Aty Hoda, Murray Iain, Hujairi Nabil, Tunariu Nina, James Nick
Аннотация
BACKGROUND: This study evaluates the utility of quantitative imaging biomarkers derived from whole-body diffusion-weighted MRI (WB-DWMRI) and [68Ga]GaPSMA-PET/CT in predicting lesion-level response to [177Lu]LuPSMA therapy in metastatic castration-resistant prostate cancer (mCRPC).
METHODS: Twenty-two patients with mCRPC who underwent WB-DWMRI and [68Ga]GaPSMA-PET/CT within three months before [177Lu]LuPSMA therapy were identified. The PSMA SUV (SUVmean, SUVSD, SUVpeak) and corresponding diffusion weighted imaging (DWI) parameters (ADCmean, ADCkurtosis, ADCvol) were extracted from five hottest lesions (highest SUVmean) on PSMA-PET/CT. Lesion response was assessed using modified PERCIST and MET-RADS-P criteria. Multilevel logistic regression and area under receiver operating characteristic (AUROC) analyses identified predictive biomarkers.
RESULTS: 65 bone lesions and 30 lymph nodes were analysed pre- and post-therapy. Forty-four (68%) bone and 16 (53%) lymph nodes lesions responded to treatment. SUVmean and SUVpeak were almost identical (rank-correlation = 0.97) and had high predictive performance for response with AUROC of 0.74 (95% CI: 0.62-0.86) and 0.75 (95% CI: 0.61-0.88) respectively. Lesion volume showed good performance (AUROC = 0.69, 95% CI 0.57-0.82) and moderately correlated with SUVmean (rank-correlation = 0.43). Neither ADCmean (AUROC = 0.45, p = 0.47) or ADCkurtosis (AUROC = 0.49, p = 0.171) were predictive. On regression modelling, a 1-unit volume increase, raised response odds by 4.3 (95% CI 0.7-27) in bone lesions, and 6.2 (95% CI 0.6-67) in lymph nodes (p = 0.06). A 1-unit SUVmean increase raised response odds by 1.5 (95% CI 1.1-2.0) in bone lesions and 1.2 (95% CI 1.0-1.4) in lymph nodes (p < 0.01). No evidence suggested combining volume with SUVmean enhanced predictive performance over SUVmean alone (p = 0.58).
CONCLUSIONS: Baseline PSMA SUVmean, SUVpeak, and volume are promising predictive biomarkers for lesion-level response to [177Lu]LuPSMA therapy. Combining functional and structural imaging biomarkers could improve treatment stratification and response assessment. Further validation in larger studies, alongside patient-level analysis, and expansion beyond the five lesions is needed to refine predictive models for clinical application.
METHODS: Twenty-two patients with mCRPC who underwent WB-DWMRI and [68Ga]GaPSMA-PET/CT within three months before [177Lu]LuPSMA therapy were identified. The PSMA SUV (SUVmean, SUVSD, SUVpeak) and corresponding diffusion weighted imaging (DWI) parameters (ADCmean, ADCkurtosis, ADCvol) were extracted from five hottest lesions (highest SUVmean) on PSMA-PET/CT. Lesion response was assessed using modified PERCIST and MET-RADS-P criteria. Multilevel logistic regression and area under receiver operating characteristic (AUROC) analyses identified predictive biomarkers.
RESULTS: 65 bone lesions and 30 lymph nodes were analysed pre- and post-therapy. Forty-four (68%) bone and 16 (53%) lymph nodes lesions responded to treatment. SUVmean and SUVpeak were almost identical (rank-correlation = 0.97) and had high predictive performance for response with AUROC of 0.74 (95% CI: 0.62-0.86) and 0.75 (95% CI: 0.61-0.88) respectively. Lesion volume showed good performance (AUROC = 0.69, 95% CI 0.57-0.82) and moderately correlated with SUVmean (rank-correlation = 0.43). Neither ADCmean (AUROC = 0.45, p = 0.47) or ADCkurtosis (AUROC = 0.49, p = 0.171) were predictive. On regression modelling, a 1-unit volume increase, raised response odds by 4.3 (95% CI 0.7-27) in bone lesions, and 6.2 (95% CI 0.6-67) in lymph nodes (p = 0.06). A 1-unit SUVmean increase raised response odds by 1.5 (95% CI 1.1-2.0) in bone lesions and 1.2 (95% CI 1.0-1.4) in lymph nodes (p < 0.01). No evidence suggested combining volume with SUVmean enhanced predictive performance over SUVmean alone (p = 0.58).
CONCLUSIONS: Baseline PSMA SUVmean, SUVpeak, and volume are promising predictive biomarkers for lesion-level response to [177Lu]LuPSMA therapy. Combining functional and structural imaging biomarkers could improve treatment stratification and response assessment. Further validation in larger studies, alongside patient-level analysis, and expansion beyond the five lesions is needed to refine predictive models for clinical application.
Предметные рубрики MeSH
HumansMaleDiffusion Magnetic Resonance ImagingProstatic Neoplasms, Castration-ResistantPositron Emission Tomography Computed TomographyWhole Body ImagingAgedLutetiumMiddle AgedRadioisotopesBiomarkers, TumorRadiopharmaceuticalsOrganometallic CompoundsGallium RadioisotopesHeterocyclic Compounds, 1-RingGallium Isotopes